Fig. 4From: Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspectsThe distribution of CVws per BCS class. Class I: Trials with BCS Class I active pharmaceutical ingredients. Class II: Trials with BCS Class II active pharmaceutical ingredients. Class III: Trials with BCS Class III active pharmaceutical ingredients. Class IV: Trials with Class IV active pharmaceutical ingredients Back to article page